Developer docs
API playgroundTry for free, no card

Search company profiles

Multitude Therapeutics

Full company profile

uuid0008paz

Namestring
Multitude Therapeutics
Legal namestring
普众发现医药科技(上海)股份有限公司
Company typeenum
Private
Founded yearint
2020
Descriptiontext

Multitude Therapeutics (普众发现医药科技(上海)股份有限公司) is a clinical-stage biotechnology company headquartered in Shanghai, China, developing antibody-drug conjugate (ADC) therapies for the treatment of solid tumors. The company was founded in 2020 and operates with a headcount of 11–50 employees. Its pipeline comprises six ADC candidates — AMT-116 (CD44v9), AMT-253 (MUC18), AMT-676 (CDH17), AMT-562 (HER3), AMT-707 (CDH6), and AMT-754 (TF) — targeting multiple solid tumor indications including EGFR wild-type non-small cell lung cancer, melanoma, soft tissue sarcoma, colorectal cancer, and gynecological cancers. Multiple candidates are positioned as potential first-in-class molecules against their respective targets.

The company's R&D is anchored by two proprietary platforms. The PAD (Precision ADC Design) Molecular Design Platform integrates tumor-biology insight with ADC structural design expertise to engineer constructs that balance potency, tumor selectivity, and off-target toxicity minimization, incorporating proprietary linker systems (e.g., the protease-sensitive, polysarcosine-modified T1000 linker) and payload systems (including an exatecan-based TOP1 inhibitor platform published in Cancer Discovery 2023). The MabArray Target Discovery Platform uses an industrialized hybridoma system and an ultra-high-density monoclonal antibody library of approximately 100,000 clones to enable large-scale screening for novel tumor antigens, feeding a continuous pipeline of new ADC-ready targets. Clinical trials are run in Australia, the United States, and China, with AMT-253 having secured U.S. FDA Orphan Drug Designation for soft tissue sarcoma (March 2026) and China CDE Breakthrough Therapy Designation for melanoma (December 2025).

The business model is pre-revenue: Multitude does not yet have commercialized products and has not disclosed product pricing. Revenue is intended to be generated through a combination of future product sales and out-licensing/partnership agreements; two deals are already in place — AMT-707 was out-licensed to OnCusp Therapeutics in 2022 for U.S. development, and AMT-754 was out-licensed to Adcendo ApS in August 2024 for global rights excluding Greater China. A technology collaboration with Kelun-Biotech supplies the KL610023 TOP1 inhibitor payload used in AMT-116. The company has been funded through angel/Pre-A rounds (2020–2021), a Series A (2023), and a Series A+ (2025), with disclosed participation from Northern Light Venture Capital and Spinnotec in 2021.

Short descriptiontext

Multitude Therapeutics is a clinical-stage Chinese biotechnology company developing antibody-drug conjugate (ADC) therapies for solid tumors, leveraging proprietary PAD and MabArray platforms to advance six first-in-class ADC candidates through clinical trials in China, the US, and Australia.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersRedwood City, United States
HQ citystring
Redwood City
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
antibody-drug conjugates, ADC therapeutics, oncology drug development, solid tumor therapy, targeted cancer biologics
Industry4 codes
PRIMARYHLAAAAAE
Antibody-Drug Conjugates (ADCs) & Antibody Conjugates
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAAAA
Monoclonal Antibody Therapeutics (mAbs)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Oncology Biopharmaceuticals (Antibody-Drug Conjugates)
Social media profiles1 record
Revenue model2 records
1ADC Drug Development and Commercialization
TypeLicensing Royalties
Description

Pre-revenue clinical stage company focused on developing ADC therapeutics through clinical stages. Revenue will come from product sales and out-licensing/partnership agreements once products reach commercialization.

multitudetherapeutics.com
2Out-licensing and Partnership Revenue
TypeLicensing Royalties
Description

The company generates revenue through out-licensing agreements with partners. AMT-754 was out-licensed to Adcendo for global development (except Greater China), and AMT-707 was out-licensed to OnCusp.

multitudetherapeutics.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Multitude Therapeutics is a clinical-stage biotechnology company developing antibody-drug conjugate (ADC) therapeutics for solid tumors. Its pipeline comprises six ADC candidates built on two proprietary platforms — the PAD Molecular Design Platform for rational ADC construct design and the MabArray Target Discovery Platform, an industrialized hybridoma system with approximately 100,000 monoclonal antibody clones for novel tumor antigen discovery. Current revenue is generated through out-licensing agreements with partners Adcendo (AMT-754) and OnCusp (AMT-707).

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • AMT-253 in melanoma: ORR of 28.6% (16/56) across all dose levels; 41.7% ORR in chemotherapy-naive patients; mPFS of 8.5 months
+2 more records
Product overview1 text field

Multitude Therapeutics is a clinical-stage biotechnology company developing a portfolio of Antibody-Drug Conjugate (ADC) therapies for solid tumors. The company's core products include six ADC candidates: AMT-116 (CD44v9-directed, Phase I/II), AMT-253 (MUC18-directed, Phase I/II), AMT-676 (CDH17-directed, Phase I), AMT-562 (HER3-targeted, preclinical), AMT-707 (CDH6-directed, Phase I), and AMT-754 (TF-directed, licensed out). These ADC candidates are developed using two proprietary technology platforms: the PAD Molecular Design Platform for rational ADC structure design and the MabArray Target Discovery Platform for identifying novel tumor-specific targets.

Product and service6 records
1AMT-116
CategoryClinical-stage ADC candidate
Description

A potential first-in-class CD44v9-directed ADC with drug-to-antibody ratio of 7-8, using a hydrolysable linker and the KL610023 topoisomerase I inhibitor payload. In Phase I/II clinical evaluation for EGFR wild-type NSCLC and other advanced solid tumors.

2AMT-253
CategoryClinical-stage ADC candidate
Description

A potential first-in-class MUC18-directed ADC with drug-to-antibody ratio of 8, using a protease-cleavable linker and exatecan payload. In Phase I/II evaluation for melanoma, gynecologic cancers, and soft tissue sarcoma. Holds FDA Orphan Drug Designation (soft tissue sarcoma) and CDE Breakthrough Therapy Designation (melanoma).

3AMT-676
CategoryClinical-stage ADC candidate
Description

The world's first clinical-stage CDH17-targeted ADC with drug-to-antibody ratio of 4, using a TOP1 inhibitor payload via the proprietary T1000 protease-cleavable linker. Intended for colorectal cancer and other solid tumors.

4AMT-562
CategoryADC candidate (preclinical)
Description

A HER3-targeted ADC candidate with average drug-to-antibody ratio of 8, using an exatecan topoisomerase I inhibitor payload via an optimized self-immolative PABC spacer. Preclinical studies show strong antitumor activity in HER3-expressing tumors.

5AMT-707
CategoryClinical-stage ADC candidate (out-licensed)
Description

A CDH6-directed ADC candidate with average drug-to-antibody ratio of 8, using an exatecan payload via a proprietary protease-sensitive polysarcosine-modified peptide linker. Out-licensed to OnCusp Therapeutics for U.S. Phase Ia development, showing potent antitumor activity in ovarian, kidney, and cholangiocarcinoma preclinical models.

6AMT-754 (ADCE-T02)
CategoryClinical-stage ADC candidate (out-licensed)
Description

A Tissue Factor (TF)-targeted ADC candidate with average drug-to-antibody ratio of 4, using a protease-cleavable Val-Ala dipeptide linker conjugated to exatecan. Out-licensed to Adcendo ApS for global development outside Greater China (renamed ADCE-T02).

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2024-08-01
Description

Strategic partnership established in August 2024, granting Adcendo exclusive global development and commercialization rights (except Greater China) for AMT-754 (anti-TF ADC, internally developed by Multitude). Adcendo is a Copenhagen-based biotech focused on first-in-class ADCs for cancers with high unmet medical needs. The partnership includes advancement of ADCE-T02 (formerly AMT-754) in Phase I Tiffany-01 clinical trials.

Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2022-01-01
Description

Out-licensing and development agreement for AMT-707 (CDH6 ADC) entered in 2022. OnCusp sponsors and conducts the Phase Ia clinical trial of AMT-707 (NCT06234423) in the US. This partnership enables the advancement of the CDH6-targeted ADC program through multinational clinical development.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage German biotech developing ADCs with proprietary linker and payload platforms (P5 conjugation and TOP1i payload platforms). Comparable to Multitude as a clinical-stage ADC specialist with proprietary platform technology targeting solid tumors.

TypeDirect peer
Description

Clinical-stage ADC developer focused on novel targets in solid tumors. ProfoundBio has developed multiple ADC candidates using proprietary linker-payload technology and recently received acquisition interest from major pharma, making it a near-perfect comparable for Multitude's clinical stage and platform approach.

TypeEmerging player
Description

Clinical-stage ADC and immuno-oncology company with multiple candidates including PYX-201 (first-in-class Extradherin-targeting ADC). Comparable as an emerging clinical-stage ADC developer with first-in-class programs and platform approach, though with fewer candidates in the clinic.

TypeBroad incumbent
Description

Japanese global pharmaceutical leader in ADC space (Enhertu, Datroway with AstraZeneca; raludotatug deruxtecan). Sets the competitive standard for ADC development and is the most likely strategic acquirer or partner for emerging ADC players like Multitude.

TypeDirect peer
Description

Clinical-stage biotechnology company developing ADCs with proprietary platforms (Dolasynthen and Immunosynthen). Closely comparable as a clinical-stage ADC-focused biotech with multiple candidates in oncology and similar partnership/out-licensing strategy.

TypeDirect peer
Description

South Korea-based clinical-stage biotech developing ADCs with proprietary conjugation technology (ConjuAll) and multiple oncology candidates in clinical development. Comparable as clinical-stage ADC platform company with similar scope and partnerships with multinational pharma.

TypeBroad incumbent
Description

Pioneer in ADC development (Elahere, Kadcyla originator) acquired by AbbVie in 2024. Represents the exit pathway that platform ADC companies aim for via acquisition by large pharma. Comparable as the established incumbent whose business model Multitude's platform aspires to emulate.

TypeDirect peer
Description

China-based biopharmaceutical company with multiple approved oncology biologics and a growing ADC pipeline (IBI354, IBI3016, etc.). Directly comparable as a Chinese ADC developer with global ambitions and similar target classes including HER3.

TypeDirect peer
Description

Chinese clinical-stage biopharmaceutical company with multiple ADC programs including SKB264 (TROP2 ADC). Kelun-Biotech is both a comparable peer and a collaborating partner (supplies KL610023 TOP1 payload for AMT-116), making it highly relevant for assessing the China ADC competitive landscape.

TypeDirect peer
Description

Copenhagen-based clinical-stage biotech developing first-in-class ADCs for cancers with high unmet needs. Adcendo licenses AMT-754 from Multitude (renamed ADCE-T02) and is a direct partner. Highly comparable clinical-stage ADC developer with similar target focus and partnership-driven business model.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Multitude Therapeutics

Oncology Biopharmaceuticals (Antibody-Drug Conjugates)multitudetherapeutics.com

Multitude Therapeutics is a clinical-stage Chinese biotechnology company developing antibody-drug conjugate (ADC) therapies for solid tumors, leveraging proprietary PAD and MabArray platforms to advance six first-in-class ADC candidates through clinical trials in China, the US, and Australia.

What Multitude Therapeutics does

Multitude Therapeutics (普众发现医药科技(上海)股份有限公司) is a clinical-stage biotechnology company headquartered in Shanghai, China, developing antibody-drug conjugate (ADC) therapies for the treatment of solid tumors. The company was founded in 2020 and operates with a headcount of 11–50 employees. Its pipeline comprises six ADC candidates — AMT-116 (CD44v9), AMT-253 (MUC18), AMT-676 (CDH17), AMT-562 (HER3), AMT-707 (CDH6), and AMT-754 (TF) — targeting multiple solid tumor indications including EGFR wild-type non-small cell lung cancer, melanoma, soft tissue sarcoma, colorectal cancer, and gynecological cancers. Multiple candidates are positioned as potential first-in-class molecules against their respective targets.

The company's R&D is anchored by two proprietary platforms. The PAD (Precision ADC Design) Molecular Design Platform integrates tumor-biology insight with ADC structural design expertise to engineer constructs that balance potency, tumor selectivity, and off-target toxicity minimization, incorporating proprietary linker systems (e.g., the protease-sensitive, polysarcosine-modified T1000 linker) and payload systems (including an exatecan-based TOP1 inhibitor platform published in Cancer Discovery 2023). The MabArray Target Discovery Platform uses an industrialized hybridoma system and an ultra-high-density monoclonal antibody library of approximately 100,000 clones to enable large-scale screening for novel tumor antigens, feeding a continuous pipeline of new ADC-ready targets. Clinical trials are run in Australia, the United States, and China, with AMT-253 having secured U.S. FDA Orphan Drug Designation for soft tissue sarcoma (March 2026) and China CDE Breakthrough Therapy Designation for melanoma (December 2025).

The business model is pre-revenue: Multitude does not yet have commercialized products and has not disclosed product pricing. Revenue is intended to be generated through a combination of future product sales and out-licensing/partnership agreements; two deals are already in place — AMT-707 was out-licensed to OnCusp Therapeutics in 2022 for U.S. development, and AMT-754 was out-licensed to Adcendo ApS in August 2024 for global rights excluding Greater China. A technology collaboration with Kelun-Biotech supplies the KL610023 TOP1 inhibitor payload used in AMT-116. The company has been funded through angel/Pre-A rounds (2020–2021), a Series A (2023), and a Series A+ (2025), with disclosed participation from Northern Light Venture Capital and Spinnotec in 2021.

Multitude Therapeutics firmographics

Firmographics
Name
Multitude Therapeutics
Legal name
普众发现医药科技(上海)股份有限公司
Website
https://multitudetherapeutics.com
Company type
Private
Founded year
2020
Operating status
Operating
Headcount range
1–10 employees
Short description
Multitude Therapeutics is a clinical-stage Chinese biotechnology company developing antibody-drug conjugate (ADC) therapies for solid tumors, leveraging proprietary PAD and MabArray platforms to advance six first-in-class ADC candidates through clinical trials in China, the US, and Australia.
Ownership category
akta.pro rank

Multitude Therapeutics industry classification

Industry
Product category
Oncology Biopharmaceuticals (Antibody-Drug Conjugates)
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAAAE
Antibody-Drug Conjugates (ADCs) & Antibody Conjugates
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAAAA
Monoclonal Antibody Therapeutics (mAbs)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • Antibody-drug conjugates
  • ADC therapeutics
  • Oncology drug development
  • Solid tumor therapy
  • Targeted cancer biologics

Where Multitude Therapeutics is headquartered

Location

Headquarters

HQ city
Redwood City
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Multitude Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

  1. ADC Drug Development and Commercialization: Pre-revenue clinical stage company focused on developing ADC therapeutics through clinical stages. Revenue will come from product sales and out-licensing/partnership agreements once products reach commercialization.
  2. Out-licensing and Partnership Revenue: The company generates revenue through out-licensing agreements with partners. AMT-754 was out-licensed to Adcendo for global development (except Greater China), and AMT-707 was out-licensed to OnCusp.

Distribution channels1 record

Marketing channels3 records

Multitude Therapeutics product offering

Product offering

Core offering

Multitude Therapeutics is a clinical-stage biotechnology company developing antibody-drug conjugate (ADC) therapeutics for solid tumors. Its pipeline comprises six ADC candidates built on two proprietary platforms — the PAD Molecular Design Platform for rational ADC construct design and the MabArray Target Discovery Platform, an industrialized hybridoma system with approximately 100,000 monoclonal antibody clones for novel tumor antigen discovery. Current revenue is generated through out-licensing agreements with partners Adcendo (AMT-754) and OnCusp (AMT-707).

Product overview

Multitude Therapeutics is a clinical-stage biotechnology company developing a portfolio of Antibody-Drug Conjugate (ADC) therapies for solid tumors. The company's core products include six ADC candidates: AMT-116 (CD44v9-directed, Phase I/II), AMT-253 (MUC18-directed, Phase I/II), AMT-676 (CDH17-directed, Phase I), AMT-562 (HER3-targeted, preclinical), AMT-707 (CDH6-directed, Phase I), and AMT-754 (TF-directed, licensed out). These ADC candidates are developed using two proprietary technology platforms: the PAD Molecular Design Platform for rational ADC structure design and the MabArray Target Discovery Platform for identifying novel tumor-specific targets.

Differentiator

Problem solved

Functional benefit

Products and services

  • AMT-116 A potential first-in-class CD44v9-directed ADC with drug-to-antibody ratio of 7-8, using a hydrolysable linker and the KL610023 topoisomerase I inhibitor payload. In Phase I/II clinical evaluation for EGFR wild-type NSCLC and other advanced solid tumors.
  • AMT-253 A potential first-in-class MUC18-directed ADC with drug-to-antibody ratio of 8, using a protease-cleavable linker and exatecan payload. In Phase I/II evaluation for melanoma, gynecologic cancers, and soft tissue sarcoma. Holds FDA Orphan Drug Designation (soft tissue sarcoma) and CDE Breakthrough Therapy Designation (melanoma).
  • AMT-676 The world's first clinical-stage CDH17-targeted ADC with drug-to-antibody ratio of 4, using a TOP1 inhibitor payload via the proprietary T1000 protease-cleavable linker. Intended for colorectal cancer and other solid tumors.
  • AMT-562 A HER3-targeted ADC candidate with average drug-to-antibody ratio of 8, using an exatecan topoisomerase I inhibitor payload via an optimized self-immolative PABC spacer. Preclinical studies show strong antitumor activity in HER3-expressing tumors.
  • AMT-707 A CDH6-directed ADC candidate with average drug-to-antibody ratio of 8, using an exatecan payload via a proprietary protease-sensitive polysarcosine-modified peptide linker. Out-licensed to OnCusp Therapeutics for U.S. Phase Ia development, showing potent antitumor activity in ovarian, kidney, and cholangiocarcinoma preclinical models.
  • AMT-754 (ADCE-T02) A Tissue Factor (TF)-targeted ADC candidate with average drug-to-antibody ratio of 4, using a protease-cleavable Val-Ala dipeptide linker conjugated to exatecan. Out-licensed to Adcendo ApS for global development outside Greater China (renamed ADCE-T02).

Quantifiable outcome

  • AMT-253 in melanoma: ORR of 28.6% (16/56) across all dose levels; 41.7% ORR in chemotherapy-naive patients; mPFS of 8.5 months
  • +2 more outcomes

Companies that use Multitude Therapeutics

Customer profile

Segments5 records

Ideal customer profiles1 record

Multitude Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Multitude Therapeutics partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • Adcendo ApScoreOEM/ Whitelabel/ Licensing Partner · 1 August 2024Strategic partnership established in August 2024, granting Adcendo exclusive global development and commercialization rights (except Greater China) for AMT-754 (anti-TF ADC, internally developed by Multitude). Adcendo is a Copenhagen-based biotech focused on first-in-class ADCs for cancers with high unmet medical needs. The partnership includes advancement of ADCE-T02 (formerly AMT-754) in Phase I Tiffany-01 clinical trials.
  • OnCusp Therapeutics InccoreOEM/ Whitelabel/ Licensing Partner · 1 January 2022Out-licensing and development agreement for AMT-707 (CDH6 ADC) entered in 2022. OnCusp sponsors and conducts the Phase Ia clinical trial of AMT-707 (NCT06234423) in the US. This partnership enables the advancement of the CDH6-targeted ADC program through multinational clinical development.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Multitude Therapeutics competitors and assessment

Company assessment

Direct peers

  • Tubulis: Clinical-stage German biotech developing ADCs with proprietary linker and payload platforms (P5 conjugation and TOP1i payload platforms). Comparable to Multitude as a clinical-stage ADC specialist with proprietary platform technology targeting solid tumors.
  • ProfoundBio: Clinical-stage ADC developer focused on novel targets in solid tumors. ProfoundBio has developed multiple ADC candidates using proprietary linker-payload technology and recently received acquisition interest from major pharma, making it a near-perfect comparable for Multitude's clinical stage and platform approach.
  • Mersana Therapeutics: Clinical-stage biotechnology company developing ADCs with proprietary platforms (Dolasynthen and Immunosynthen). Closely comparable as a clinical-stage ADC-focused biotech with multiple candidates in oncology and similar partnership/out-licensing strategy.
  • LegoChem Biosciences: South Korea-based clinical-stage biotech developing ADCs with proprietary conjugation technology (ConjuAll) and multiple oncology candidates in clinical development. Comparable as clinical-stage ADC platform company with similar scope and partnerships with multinational pharma.
  • Innovent Biologics: China-based biopharmaceutical company with multiple approved oncology biologics and a growing ADC pipeline (IBI354, IBI3016, etc.). Directly comparable as a Chinese ADC developer with global ambitions and similar target classes including HER3.
  • Kelun-Biotech: Chinese clinical-stage biopharmaceutical company with multiple ADC programs including SKB264 (TROP2 ADC). Kelun-Biotech is both a comparable peer and a collaborating partner (supplies KL610023 TOP1 payload for AMT-116), making it highly relevant for assessing the China ADC competitive landscape.
  • Adcendo ApS: Copenhagen-based clinical-stage biotech developing first-in-class ADCs for cancers with high unmet needs. Adcendo licenses AMT-754 from Multitude (renamed ADCE-T02) and is a direct partner. Highly comparable clinical-stage ADC developer with similar target focus and partnership-driven business model.

Emerging players

  • Pyxis Oncology: Clinical-stage ADC and immuno-oncology company with multiple candidates including PYX-201 (first-in-class Extradherin-targeting ADC). Comparable as an emerging clinical-stage ADC developer with first-in-class programs and platform approach, though with fewer candidates in the clinic.

Broad incumbents

  • Daiichi Sankyo: Japanese global pharmaceutical leader in ADC space (Enhertu, Datroway with AstraZeneca; raludotatug deruxtecan). Sets the competitive standard for ADC development and is the most likely strategic acquirer or partner for emerging ADC players like Multitude.
  • ImmunoGen (AbbVie): Pioneer in ADC development (Elahere, Kadcyla originator) acquired by AbbVie in 2024. Represents the exit pathway that platform ADC companies aim for via acquisition by large pharma. Comparable as the established incumbent whose business model Multitude's platform aspires to emulate.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Multitude Therapeutics social profiles

Digital presence

Multitude Therapeutics compliance and trust

Trust signal

Compliance2 records

Multitude Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Multitude Therapeutics leadership team

Management profile

Number of profiles

Profiles3 records

Multitude Therapeutics funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Multitude Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Multitude Therapeutics

What does Multitude Therapeutics do?

Multitude Therapeutics is a clinical-stage biotechnology company developing antibody-drug conjugate (ADC) therapeutics for solid tumors. Its pipeline comprises six ADC candidates built on two proprietary platforms — the PAD Molecular Design Platform for rational ADC construct design and the MabArray Target Discovery Platform, an industrialized hybridoma system with approximately 100,000 monoclonal antibody clones for novel tumor antigen discovery. Current revenue is generated through out-licensing agreements with partners Adcendo (AMT-754) and OnCusp (AMT-707).

Is Multitude Therapeutics a public or private company?

Multitude Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Multitude Therapeutics founded?

Multitude Therapeutics was founded in 2020. It employs 1 to 10 people.

Where is Multitude Therapeutics based?

Multitude Therapeutics is headquartered in Redwood City, United States, in the North America region.

How does Multitude Therapeutics make money?

Two revenue lines are on record. ADC Drug Development and Commercialization is the primary driver. The others are out-licensing and Partnership Revenue.

Who are Multitude Therapeutics's main competitors?

Direct peers on record are Tubulis, ProfoundBio, Mersana Therapeutics, LegoChem Biosciences, Innovent Biologics, Kelun-Biotech and Adcendo ApS. Pyxis Oncology is listed as an emerging player. Broad incumbents are Daiichi Sankyo and ImmunoGen (AbbVie).

Does Multitude Therapeutics have an API?

No public API is recorded for Multitude Therapeutics.

What industry is Multitude Therapeutics in?

Multitude Therapeutics's product category is Oncology Biopharmaceuticals (Antibody-Drug Conjugates). Its primary akta.pro industry code is HLAAAAAE, Antibody-Drug Conjugates (ADCs) & Antibody Conjugates, with a secondary code of HLAAAIAB, Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireMultitude Therapeutics Announces Encouraging Interim Phase I/II Results from Ongoing First-in-Human Study Evaluating its MUC18-directed Antibody-Drug-Conjugate, AMT-253, in Melanoma and Other AdvancedMultitude Therapeutics announced interim Phase I/II clinical trial results for AMT-253, a MUC18-directed antibody-drug-conjugate, at the 2025 ESMO Annual Meeting, with trials conducted in Australia and China. The study reported an overall response rate of 28.6% in heavily pretreated melanoma patients (16/56) across all dose levels, with 35% ORR in cutaneous melanoma patients without prior chemotherapy and preliminary median progression-free survival ranging from 8.3 to 11.0 months depending on subtype. The ADC demonstrated a manageable safety profile consistent with other TOP1-inhibitor based ADCs, with no treatment-related neuropathy or pneumonitis observed as of the September 8, 2025 data cutoff.PR NewswireMultitude Therapeutics Announces Promising Interim Phase I/II Results from the Ongoing First-in-Human Study Evaluating its CD44v9-directed Antibody-Drug-Conjugate, AMT-116, in Heavily Pretreated EGFRMultitude Therapeutics announced initial Phase I/II data for AMT-116, its CD44v9-directed antibody-drug-conjugate (ADC), in patients with heavily pretreated EGFR wild-type NSCLC and other advanced solid tumors, with results presented at the 2025 ESMO Annual Meeting in Berlin, Germany. In EGFR wild-type NSCLC patients at doses above 3 mg/kg, the overall response rate was 40% (6/15) and disease control rate was 93% (14/15), rising to 80% ORR and 100% DCR at the 5.0 mg/kg dose level; promising activity was also seen in nasopharyngeal carcinoma, anal carcinoma, and salivary gland cancer. The trial enrolled 164 patients across Australia, the US, and China, and the ADC demonstrated a favorable safety profile with manageable hematologic and gastrointestinal toxicities and notably low-grade mucosal and skin toxicities.PR Newswire APACMultitude Therapeutics Announces Promising Interim Phase I/II Results from the Ongoing First-in-Human Study Evaluating its CD44v9-directed Antibody-Drug-Conjugate, AMT-116, in Heavily Pretreated EGFRMultitude Therapeutics announced promising interim Phase I/II results for AMT-116, a CD44v9-directed antibody-drug conjugate, in heavily pretreated EGFR wild-type NSCLC patients and other advanced solid tumors, with the trials conducted across Australia, the US, and China. The drug demonstrated a favorable safety profile with manageable toxicities and strong efficacy, achieving a 40% overall response rate and 93% disease control rate in EGFR wild-type NSCLC patients at doses above 3 mg/kg, rising to 80% ORR and 100% DCR at the 5.0 mg/kg dose level. The company is expanding enrollment at the 4 mg/kg and 5 mg/kg dose cohorts and presented the findings at the 2025 ESMO Annual Meeting in Berlin, Germany.biopharma-reporter.comAdcendo and Multitude target cancer resistance to ADCs in $1BN dealAdcendo and Multitude agreed to a deal worth over $1 billion in milestone payments for ADC candidate ADCE-T02. The candidate targets tissue factor and is due to begin clinical testing in Australia later this year. Adcendo expects to become a clinical-stage biotech in Q4 2024.YahooAdcendo and Multitude ink ADC deal potentially worth $1bnAdcendo signed a licensing agreement with Multitude for its tissue factor-targeting ADC candidate ADCE-T02, potentially worth over $1bn in upfront and milestone payments. The deal gives Adcendo global rights except in Greater China, with a Phase I trial expected in Australia in Q4 2024.PR NewswireWuXi XDC Enters into Partnership with Multitude Therapeutics and HySlink Therapeutics, Novel Linker-Payload Technology Enabling Clients to Accelerate ADC Discovery and DevelopmentWuXi XDC announced a partnership with Multitude Therapeutics and HySlink Therapeutics for co-developing drug-linker technology and providing CRDMO services. The collaboration aims to accelerate ADC discovery and development, with the technology potentially expanding the therapeutic window of existing ADC drugs.PR NewswireOnCusp Therapeutics and Multitude Therapeutics Enter into an Ex-China Licensing Agreement for a Potentially Highly Differentiated CDH6-Targeting Antibody Drug ConjugateOnCusp Therapeutics announced a licensing agreement with Multitude Therapeutics for exclusive global rights outside of Greater China to develop and commercialize CUSP06, a second-in-class CDH6 antibody drug conjugate for multiple solid malignancies. Multitude will receive an upfront payment along with development, regulatory, and sales milestone payments, plus tiered royalties. The ADC is currently in Investigational New Drug-enabling studies and was developed using Multitude's MabArray antibody platform and T1000 linker/payload technology.